{"id":"W3204458306","doi":"10.1016/j.annonc.2021.08.248","title":"1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"Roche; Merck KGaA; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Carboplatin; Nivolumab; Etoposide; Monoclonal antibody; Chemotherapy; Antibody; Oncology; Internal medicine; Cytotoxicity; Cancer research; Pharmacology; Immunotherapy; Immunology; Cancer; In vitro; Cisplatin; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009696,0.001568509,0.002484096,0.0004594235,0.0003758981,0.001087023,0.0007712899,0.001592661,0.008993717],"category_scores_gemma":[0.0006517469,0.00070205,0.001583035,0.0004203884,0.0008724723,0.0007900809,0.0003633382,0.003359461,0.001790786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007143826,"about_ca_system_score_gemma":0.001233283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009101427,"about_ca_topic_score_gemma":0.002575912,"domain_scores_codex":[0.9996694,0.0001658511,0.00001730725,0.00005583447,0.00002143619,0.00007021576],"domain_scores_gemma":[0.999613,0.00006357599,0.00005792514,0.0000278131,0.00002563592,0.0002121729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9519359,0.0107168,0.001259438,0.0004394798,0.0009765864,0.0000516165,0.00003580137,0.0005702014,0.007278455,0.000168069,0.001701909,0.02486573],"study_design_scores_gemma":[0.9056029,0.08920553,0.002420555,0.00001591719,0.0004657733,0.00004050021,0.0000170285,0.0004035434,0.0006189751,0.0001220548,0.001072653,0.00001458631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986858,0.002835469,0.0005492788,0.0008855045,0.0006327492,0.002885576,0.00173963,0.0001895071,0.003424208],"genre_scores_gemma":[0.9786476,0.002338979,0.00190856,0.002160685,0.000510145,0.003100003,0.003628365,0.00004729326,0.007658425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008993717,"threshold_uncertainty_score":0.03008699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0357197452818391,"score_gpt":0.3796379834659818,"score_spread":0.3439182381841427,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}